ANGLE (LON:AGL)‘s stock had its “corporate” rating reissued by equities researchers at FinnCap in a research report issued on Monday, March 26th. They currently have a GBX 108 ($1.55) target price on the stock. FinnCap’s price target indicates a potential upside of 134.78% from the company’s current price.
LON:AGL remained flat at $GBX 46 ($0.66) during trading hours on Monday. 58,280 shares of the company traded hands, compared to its average volume of 106,228. ANGLE has a 1 year low of GBX 32.27 ($0.46) and a 1 year high of GBX 80 ($1.15).
COPYRIGHT VIOLATION WARNING: “ANGLE (AGL) Earns Corporate Rating from FinnCap” was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://stocknewstimes.com/2018/04/17/angle-agl-receives-corporate-rating-from-finncap.html.
ANGLE plc, a medical diagnostic company, provides cancer diagnostics and foetal health products. Its lead product is Parsortix cell separation system, which captures very rare circulating tumor cells in cancer patient blood. ANGLE plc was founded in 2004 and is based in Guildford, the United Kingdom.
Receive News & Ratings for ANGLE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANGLE and related companies with MarketBeat.com's FREE daily email newsletter.